AEGiS-PRn: Serologicals Corporation to Participate in Centers for Disease Control's HIV/HCV Risk Factor Study

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Serologicals Corporation to Participate in Centers for Disease Control's HIV/HCV Risk Factor Study

PRNewswire - Monday November 20, 2000

ATLANTA, Nov. 20 /PRNewswire/ -- Serologicals Corporation (Nasdaq: SERO - news) today announced that it has been selected to participate in a Centers for Disease Control and Prevention (CDC) HIV/HCV (Hepatitis C) Risk Factor Study. The CDC, in collaboration with Boston Biomedica, Inc. (Nasdaq: BMII - news) seeks to analyze the risk behavior characteristics of infected donors in order to improve the donor screening and deferral process. Toby Simon, M.D., vice president of Medical and Scientific Affairs at Serologicals, will serve as a co-investigator and will assist with protocol development, donor recruitment and data analysis. Through its 17 specialty-antibody donation centers located throughout the country, Serologicals will identify and recruit individuals who are deferred from the donation process because of their HIV or HCV positive status.

David A. Dodd, president and chief executive officer of Serologicals Corporation, said, ``The request by the study's sponsors that Serologicals Corporation participate in this important study reflects our demonstrated ability to identify and recruit qualified donors and effectively manage the donation process. Also, Dr. Simon, a leading expert in the blood and plasma donation process and a former president of the American Association of Blood Banks, will add significant experience and insight to the study.''

Serologicals Corporation, headquartered in Atlanta, is a leading worldwide provider of biological materials and services to pharmaceutical and life science companies. The company provides value-added antibody-based products that are used as the active ingredients in therapeutic products for the treatment and management of diseases such as Rh incompatibility in newborns, rabies and hepatitis and in diagnostic products such as blood typing reagents and diagnostic test kits. Additionally, the company, through its protein fractionation facility, provides a variety of proteins used in the manufacturing of diagnostic reagents and tissue culture media components for use as additives in biotech products.

SOURCE: Serologicals Corporation
001120
PR001121

Copyright © 2000 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .